Benzinga Microsoft''s Nadella Criticizes Google''s Exclusive Content Deals Amid Antitrust Case In a significant development, Microsoft Corp''s (NASDAQ: MSFT ) CEO, Satya Nadella , has voiced concerns over the competitive landscape of content acquisition essential for training artificial intelligence (AI). Nadella''s remarks came during his testimony in a landmark antitrust trial in the U.S., where he highlighted the challenges posed by exclusive deals that tech giants, notably Alphabet Inc (NASDAQ: GOOGL ) (NASDAQ: GOOG ) Google, are securing with publishers. AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug AstraZeneca Plc (NASDAQ: AZN ) has agreed to pay $425 million to settle U.S. lawsuits related to heartburn and stomach acid treatments Nexium and Prilosec. The heartburn treatments have been under litigation, as some users said they caused kidney damage. Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine Sanofi SA (NASDAQ: SNY ) struck a deal with Janssen Pharmaceuticals , a unit of Johnson & Johnson (NYSE: JNJ ), to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent).

Sanofi has added a late-stage can­di­date to its vac­cine fran­chise, pay­ing J&J’s Janssen $175 mil­lion up­front to part­ner on a shot that will pro­tect peo­ple from ex­train­testi­nal path­o­gen­ic E. coli. Janssen be­gan a Phase III tri­al of the …

… Janssen Pharmaceuticals . Under the terms of the deal, Sanofi will … executive vice president, vaccines at Sanofi , said: “E. coli is … than a month after Sanofi partnered with Ad Scientiam … with multiple sclerosis (MS). Sanofi also expanded its collaboration …

Sanofi SA (NASDAQ: SNY ) struck a deal with Janssen Pharmaceuticals , a unit of Johnson & Johnson (NYSE: JNJ ), to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) . The vaccine is currently in Phase 3 E.mbrace trial designed to evaluate the efficacy of the 9-valent extraintestinal pathogenic E. coli vaccine (ExPEC9V) compared to placebo in the prevention … Full story available on Benzinga.com

Sanofi partners with Janssen to develop a vaccine for extraintestinal pathogenic E. coli, a leading cause of bloodstream infections in older adults. Read more here.

NEW BRUNSWICK (dpa-AFX) - Sanofi (SNYNF) on Tuesday said it has entered into an agreement with Janssen Pharmaceuticals, Inc. , a Johnson & Johnson company, for the development of Janssen''s extrain…

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causin…

Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli Extraintestinal pathogenic E. coli (ExPEC)…

Beacon Financial Group cut its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 6.0% in the 2nd quarter, Holdings Channel reports. The firm owned 15,183 shares of the company’s stock after selling 974 shares during the quarter. Beacon Financial Group’s holdings in Sanofi were worth $805,000 as of its most recent filing with […]

Harrington Investments INC decreased its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,803 shares of the company’s stock after selling 190 shares during the quarter. Harrington Investments INC’s holdings in Sanofi […]